Table 3.
Association of hepatic fibrosis at ART initiation with all-cause mortality among HIV-infected Zambian adults
| Crude AHR (95% CI) |
Adjusted AHR (95% CI) |
|
|---|---|---|
| Hepatic fibrosis level | ||
| APRI <1.5 (No significant fibrosis) | Reference | Reference |
| APRI ≥ 1.5 (Significant fibrosis) | 2.08 (1.80–2.40) | 1.41 (1.21–1.64) |
| Age, per 10-year increase | 1.11 (1.06–1.16) | 1.10 (1.05–1.16) |
| Male sex | 1.46 (1.34–1.58) | 1.28 (1.17–1.40) |
| WHO clinical stage 3 or 4 | 2.29 (2.06–2.54) | 1.61 (1.44–1.81) |
| Body mass index | ||
| >25 | Reference | Reference |
| 18–25 | 1.67 (1.35–2.06) | 1.30 (1.05–1.62) |
| <18 | 3.75 (3.03–4.64) | 2.20 (1.76–2.74) |
| CD4+ count, cells/mm3 | ||
| >200 | Reference | Reference |
| 100–200 | 1.36 (1.20–1.54) | 1.30 (1.14–1.47) |
| <100 | 2.66 (2.39–2.97) | 2.04 (1.81–2.29) |
| ART regimen | ||
| NRTIs | ||
| D4T+3TC | Reference | Reference |
| AZT+3TC | 0.43 (0.39–0.49) | 0.51 (0.45–0.57) |
| TDF+XTC | 0.77 (0.70–0.85) | 0.82 (0.74–0.91) |
| NNRTI | ||
| NVP | Reference | Reference |
| EFV | 1.16 (1.06–1.26) | 0.85 (0.77–0.94) |
Abbreviations: ART, antiretroviral therapy; WHO, world health organization; AHR, adjusted hazard ratio; NRTI, nucleotide reverse transcriptase inhibitor; NNRTI, non-nucleotide reverse transcriptase inhibitor; D4T, stavudine; 3TC, lamivudine; XTC, either lamivudine or emtricitabine; AZT, zidovudine; TDF, tenofovir; NVP, nevirapine; EFV, efavirenz